Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast Cancer

Clinical trial NCT05955170 · RECRUITING

Trial details

NCT number: NCT05955170
Sponsor: Institut Curie
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

HER2-positive Breast Cancer

Start date: 2023-12-19
Primary completion: 2027-12-19
Enrollment: 66

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.